Quick Dispatch:
Your foxo4 dri human trials results FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway - Han - 2022 - Journal of Cellular and Molecular Medicine orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your foxo4 dri human trials results FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway - Han - 2022 - Journal of Cellular and Molecular Medicine ships.
Need Help?
Questions about foxo4 dri human trials results FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway - Han - 2022 - Journal of Cellular and Molecular Medicine, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for foxo4 dri human trials results FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway - Han - 2022 - Journal of Cellular and Molecular Medicine in your area.
FOXO4-DRI | FOXO4/p53 Interaction Blocker
25.99
FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway - Han - 2022 - Journal of Cellular and Molecular Medicine
26.72
Journal Club
23.60
FOXO4-DRI alleviates RIPF. (A) Representative Western blot for the
26.50
FOXO4-DRI (Proxofim)
23.08
FOXO4-DRI part 1 , #peptide #molecule #research #health #information
23.15
Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis
27.82
